Figure 1.

EZH2 was high-expressed in liver cancer and associated with poor survival and CD133⁺ HuH7 cells had a strong sphere-forming ability. (A) The expression of EZH2 in liver cancer tissues retrieved from the TCGA database was analyzed using GEPIA (http://gepia.cancer-pku.cn/index.html) (*P< 0.001, vs T). (B) The overall survival of liver cancer patients retrieved from the TCGA database was analyzed. (C) The expressions of EZH2 in normal liver epithelial cells and liver cancer cells were detected by RT-qPCR; GAPDH was used as an internal control (***P< 0.001, vs THLE3).(D–E) The expressions of EZH2 in normal liver epithelial cells and liver cancer cells were detected by Western blot; β-actin was used as an internal control (***P< 0.05, vs THLE3). (F) CD133⁺HuH7 cells in HuH7 cells were sorted out by flow cytometry. (G) The sphere-forming abilities of HuH7 and CD133⁺HuH7 cells were detected by tumor sphere formation assay (200× Magnification).

Abbreviations: LIHC, liver hepatocellular carcinoma; T, tumor tissues.